Vaccine Adverse Events Following COVID-19 Vaccination with Inactivated Vaccines in Zimbabwe

被引:3
|
作者
Makadzange, Azure Tariro [1 ]
Gundidza, Patricia [1 ]
Lau, Charles [2 ]
Beta, Norest [1 ]
Myburgh, Nellie [3 ]
Elose, Nyasha [1 ]
James, Wilmot [4 ]
Stanberry, Lawrence [5 ,6 ]
Ndhlovu, Chiratidzo [1 ,7 ]
机构
[1] Charles River Med Grp, 155 King George Ave, Harare, Zimbabwe
[2] RTI Int, 3040 East Cornwallis Rd, Res Triangle Pk, NC 27709 USA
[3] Univ Witwatersrand, Fac Hlth Sci, Wits Vaccines & Infect Dis Analyt VIDA Res Unit, ZA-2000 Johannesburg, South Africa
[4] Columbia Univ, Inst Social & Econ Res & Policy, IAB 118th St, New York, NY 10025 USA
[5] Columbia Univ, Vaccine Informat Network, 533 W 218th St, New York, NY 10032 USA
[6] Columbia Univ, Vagelos Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA
[7] Univ Zimbabwe, Fac Med & Hlth Sci, Dept Primary Hlth Care Sci, Internal Med Unit, POB A178, Harare, Zimbabwe
关键词
vaccine adverse events; COVID-19; vaccination; vaccine hesitancy; inactivated COVID-19 vaccine; Sinopharm vaccine; Sinovac vaccine; whole attenuated vaccine;
D O I
10.3390/vaccines10101767
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Vaccination is one of the most effective methods for preventing morbidity and mortality from COVID-19. Vaccine hesitancy has led to a decrease in vaccine uptake; driven by misinformation, fear, and misperceptions of vaccine safety. Whole inactivated vaccines have been used in one-fifth of the vaccine recipients in Africa, however there are limited real-world data on their safety. We evaluated the reported adverse events and factors associated with reported adverse events following vaccination with whole inactivated COVID-19 vaccines-BBiBP-CorV (Sinopharm) and CoronaVac (Sinovac). A quantitative survey evaluating attitudes and adverse events from vaccination was administered to 1016 adults presenting at vaccination centers. Two follow-up telephone interviews were conducted to determine adverse events after the first and second vaccination dose. Overall, the vaccine was well tolerated; 26.0% and 14.4% reported adverse events after the first and second dose, respectively. The most frequent local and systemic adverse events were pain at the injection site and headaches, respectively. Most symptoms were mild, and no participants required hospitalization. Participants who perceived COVID-19 vaccines as safe or had a personal COVID-19 experience were significantly less likely to report adverse events. Our findings provide data on the safety and tolerability of whole inactivated COVID-19 vaccines in an African population, providing the necessary data to create effective strategies to increase vaccination and support vaccination campaigns.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Adverse events report of inactivated COVID-19 vaccine from 4040 healthcare workers
    Tosun, Selma
    Ozdemir, Hulya Ozkan
    Erdogan, Esin
    Akcay, Seniz
    Aysin, Murat
    Eskut, Neslihan
    Ortan, Pinar
    Eskut, Burak
    POSTGRADUATE MEDICINE, 2022, 134 (01) : 104 - 110
  • [22] Correction: Adverse events of inactivated COVID-19 vaccine in HIV-infected adults
    Wu, Songjie
    Zhang, Yubin
    Ming, Fangzhao
    Zou, Shi
    Wu, Mengmeng
    Guo, Wei
    Tang, Weiming
    Liang, Ke
    AIDS RESEARCH AND THERAPY, 2024, 21 (01):
  • [23] Immunogenicity of inactivated COVID-19 vaccines at different vaccination intervals
    Li, Juan
    Chen, Weixin
    Chen, Meng
    Bai, Shuang
    Yuan, Qianli
    Wu, Jiang
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (10) : 3310 - 3313
  • [24] A Causality Assessment Framework for COVID-19 Vaccines and Adverse Events at the COVID-19 Vaccine Safety Research Center
    Kim, Seyoung
    Kim, Jeong Ah
    Park, Hyesook
    Park, Sohee
    Oh, Sanghoon
    Jung, Seung Eun
    Shin, Hyoung-Shik
    Lee, Jong Koo
    Han, Hee Chul
    Woo, Jun Hee
    Park, Byung-Joo
    Choi, Nam-Kyong
    Kim, Dong-Hyun
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2024, 39 (26)
  • [25] Surveillance of adverse events following immunisation in Australia, COVID-19 vaccines, 2021
    Glover, Catherine
    Deng, Lucy
    Larter, Claire
    Brogan, Catherine
    Richardson, Olivia
    Huang, Yuanfei Anny
    Kay, Elspeth
    Macartney, Kristine
    Wood, Nicholas
    COMMUNICABLE DISEASES INTELLIGENCE, 2024, 48
  • [26] Monitoring of adverse events following COVID-19 vaccines in department of veterans affairs
    Hur, Kwan
    Cunningham, Francesca
    Martin, Jennifer
    Pandey, Lucy
    Thakkar, Bharat
    Zhang, Rongping
    Salone, Cedric
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 627 - 627
  • [27] Signaling COVID-19 Vaccine Adverse Events
    Rave Harpaz
    William DuMouchel
    Robbert Van Manen
    Alexander Nip
    Steve Bright
    Ana Szarfman
    Joseph Tonning
    Magnus Lerch
    Drug Safety, 2022, 45 : 765 - 780
  • [28] Signaling COVID-19 Vaccine Adverse Events
    Harpaz, Rave
    DuMouchel, William
    Van Manen, Robbert
    Nip, Alexander
    Bright, Steve
    Szarfman, Ana
    Tonning, Joseph
    Lerch, Magnus
    DRUG SAFETY, 2022, 45 (07) : 765 - 780
  • [29] OVERVIEW OF COVID-19 VACCINE ADVERSE EVENTS
    Dobrek, Lukasz
    ACTA POLONIAE PHARMACEUTICA, 2024, 81 (04): : 577 - 601
  • [30] Assessment of the Immunogenicity of COVID-19 Heterogeneous Booster Vaccination Following the Full Immunization of Inactivated Vaccines
    Xie, FangQin
    Li, JunRong
    Yang, XiuHui
    Chen, ZhiFei
    Zhang, HaiRong
    Huang, RongDong
    Zheng, KuiCheng
    Zhang, LiNa
    Zhang, DongJuan
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2023, 37 (05): : 2377 - 2384